Amgen (NASDAQ:AMGN) Stock Price Expected to Rise, Argus Analyst Says

Amgen (NASDAQ:AMGN) had its price objective lifted by analysts at Argus from $360.00 to $400.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the medical research company’s stock. Argus’ price objective suggests a potential upside of 5.87% from the company’s current price.

Several other equities analysts also recently commented on the stock. The Goldman Sachs Group increased their price objective on shares of Amgen from $403.00 to $415.00 and gave the company a “buy” rating in a research note on Wednesday. BMO Capital Markets raised their price objective on Amgen from $335.00 to $372.00 and gave the company an “outperform” rating in a report on Wednesday, December 3rd. Leerink Partners boosted their price objective on Amgen from $305.00 to $355.00 and gave the stock an “outperform” rating in a research report on Wednesday. Guggenheim upped their target price on Amgen from $305.00 to $347.00 and gave the stock a “neutral” rating in a report on Friday. Finally, HSBC reiterated a “buy” rating and issued a $425.00 target price on shares of Amgen in a research report on Wednesday, December 10th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $351.65.

Amgen Price Performance

Shares of Amgen stock traded up $10.01 during trading on Friday, reaching $377.81. 1,108,163 shares of the company’s stock were exchanged, compared to its average volume of 2,873,542. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.99 and a current ratio of 1.14. Amgen has a 1-year low of $261.43 and a 1-year high of $377.88. The company has a market cap of $203.45 billion, a P/E ratio of 26.55, a PEG ratio of 3.20 and a beta of 0.46. The firm’s 50-day moving average price is $333.66 and its 200 day moving average price is $310.84.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The firm had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, research analysts anticipate that Amgen will post 20.62 earnings per share for the current year.

Insider Activity at Amgen

In other Amgen news, SVP Rachna Khosla sold 890 shares of the stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total transaction of $299,253.60. Following the completion of the sale, the senior vice president owned 7,082 shares of the company’s stock, valued at approximately $2,381,251.68. This represents a 11.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Nancy A. Grygiel sold 3,139 shares of Amgen stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the transaction, the senior vice president directly owned 7,225 shares of the company’s stock, valued at $2,436,703.50. This represents a 30.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 10,908 shares of company stock worth $3,674,966 over the last ninety days. Insiders own 0.76% of the company’s stock.

Institutional Investors Weigh In On Amgen

Several hedge funds and other institutional investors have recently bought and sold shares of AMGN. Dogwood Wealth Management LLC increased its holdings in shares of Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 55 shares in the last quarter. Anfield Capital Management LLC grew its position in Amgen by 1,000.0% in the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 70 shares during the period. Board of the Pension Protection Fund bought a new stake in Amgen during the 4th quarter valued at $26,000. Legacy Investment Solutions LLC acquired a new position in Amgen during the second quarter worth $27,000. Finally, Manning & Napier Advisors LLC lifted its stake in shares of Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after buying an additional 32 shares in the last quarter. 76.50% of the stock is owned by institutional investors.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q4 results and outlook beat expectations — Amgen reported better‑than‑expected quarterly results and reiterated a strong 2026 outlook, which helped momentum into 52‑week highs and supports higher valuation expectations. Amgen Q4 results beat Street estimates, company says patients need weight-loss options
• Positive Sentiment: Pipeline progress: Xaluritamig advanced into a first‑in‑human Phase 1b trial for hard‑to‑treat Ewing sarcoma — a meaningful clinical milestone that increases upside optionality for Amgen’s oncology franchise if early data are favorable. Amgen Advances Xaluritamig Into Early-Stage Trial for Hard-to-Treat Ewing Sarcoma
• Positive Sentiment: Market technicals and investor rotation into healthcare/blue‑chip biotech names have driven institutional demand and headlines about AMGN hitting buy/52‑week signals, reinforcing near‑term upside. Amgen Stock Hits 52-Week Highs: Buy Signal?
• Neutral Sentiment: Analyst actions are mixed: Guggenheim raised its price target to $347 but kept a neutral rating, and Deutsche Bank bumped its target to $295 with a hold — both moves acknowledge stronger fundamentals but their PTs sit below current levels, creating mixed signals for traders. Benzinga Deutsche Bank adjusts Amgen price target to $295 from $285, maintains hold rating
• Neutral Sentiment: IMLYGIC post‑marketing safety study reached completion — this closes a regulatory/post‑market item but is unlikely to move revenue near‑term until any safety signals or label actions emerge. Amgen’s IMLYGIC Safety Study in Melanoma Reaches Completion
• Negative Sentiment: Payer action: CVS Health will drop some Amgen bone‑disease treatments from preferred drug lists in favor of lower‑cost alternatives starting April 1 — this could pressure sales of affected products and is a tangible near‑term commercial headwind to watch. CVS Health to drop Amgen and Lilly’s bone disease treatments from some drug lists

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.